Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Phase 2

Completed

Conditions: Advanced Melanoma

Interventions: Drug: lenvatinib
Biological: pembrolizumab

First Posted Date: 2018-12-14

Last Posted Date: 2024-10-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 103

Registration Number: NCT03776136

Locations: 🇺🇸
John Wayne Cancer Institute ( Site 0301), Santa Monica, California, United States
🇺🇸
Advocate Medical Group-Park Ridge ( Site 0313), Park Ridge, Illinois, United States
🇺🇸
Southeast Nebraska Cancer Center ( Site 0316), Lincoln, Nebraska, United States

and more 20 locations

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Phase 3

Active, not recruiting

Conditions: Head and Neck Neoplasms

Interventions: Biological: Pembrolizumab 200 mg
Radiation: Radiotherapy 60 Gray
Radiation: Radiotherapy 66 Gray
Radiation: Radiotherapy 70 Gray
Drug: Cisplatin 100 mg/m^2

First Posted Date: 2018-12-05

Last Posted Date: 2025-02-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 714

Registration Number: NCT03765918

Locations: 🇺🇸
University of Maryland ( Site 2031), Baltimore, Maryland, United States
🇺🇸
Stony Brook University ( Site 2063), Stony Brook, New York, United States
🇺🇸
Rutgers Cancer Institute of New Jersey ( Site 2071), New Brunswick, New Jersey, United States

and more 189 locations

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: MK-8353
Drug: Selumetinib

First Posted Date: 2018-11-19

Last Posted Date: 2023-07-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 30

Registration Number: NCT03745989

Locations: 🇺🇸
Florida Cancer Specialists ( Site 7000), Sarasota, Florida, United States
🇺🇸
Next Oncology ( Site 0001), San Antonio, Texas, United States
🇨🇦
Princess Margaret Cancer Centre ( Site 0012), Toronto, Ontario, Canada

and more 2 locations

A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Frespaciguat
Drug: Placebo

First Posted Date: 2018-11-16

Last Posted Date: 2025-06-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 25

Registration Number: NCT03744637

Locations: 🇲🇩
Republican Clinical Hospital of Moldova ( Site 0001), Chisinau, Moldova, Republic of

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Phase 2

Active, not recruiting

Conditions: Advanced Solid Neoplasms

Interventions: Drug: Olaparib

First Posted Date: 2018-11-15

Last Posted Date: 2024-12-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 390

Registration Number: NCT03742895

Locations: 🇺🇸
The University of Arizona Cancer Center - North Campus ( Site 0011), Tucson, Arizona, United States
🇺🇸
St Joseph Heritage Healthcare-Oncology ( Site 0056), Fullerton, California, United States
🇺🇸
Cedars Sinai Medical Center ( Site 0002), Los Angeles, California, United States

and more 127 locations

Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)

Phase 1

Withdrawn

Conditions: Mild Cognitive Impairment
Alzheimer's Disease

Interventions: Drug: Placebo to MK-4334
Drug: MK-4334
Drug: Donepepzil

First Posted Date: 2018-11-14

Last Posted Date: 2025-04-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 12

Registration Number: NCT03740178

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Phase 3

Active, not recruiting

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Neoplasms

Interventions: Drug: Placebo for pembrolizumab
Biological: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Olaparib
Drug: Placebo for olaparib
Biological: Bevacizumab
Drug: Docetaxel

First Posted Date: 2018-11-14

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1367

Registration Number: NCT03740165

Locations: 🇺🇸
The Bing Cancer Center ( Site 0044), Columbus, Ohio, United States
🇺🇸
Parkland Hospital ( Site 0081), Dallas, Texas, United States
🇺🇸
UT Southwestern Medical Center ( Site 0046), Dallas, Texas, United States

and more 224 locations

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Biological: MK-4621
Biological: Pembrolizumab

First Posted Date: 2018-11-13

Last Posted Date: 2022-02-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 30

Registration Number: NCT03739138

Locations: 🇫🇷
Institut Bergonie ( Site 3303), Bordeaux, France
🇫🇷
CHU La Timone ( Site 3304), Marseille, France
🇫🇷
Institut Curie ( Site 3302), Paris, France

and more 6 locations

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: V114
Biological: Prevnar 13™

First Posted Date: 2018-11-06

Last Posted Date: 2021-06-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 104

Registration Number: NCT03731182

Locations: 🇺🇸
University of Rochester Medical Center ( Site 0105), Rochester, New York, United States
🇧🇷
Hospital Santo Antonio - Obras Sociais Irma Dulce ( Site 0205), Salvador, Brazil
🇬🇷
Agia Sophia Children s Hospital ( Site 0700), Athens, Greece

and more 16 locations

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Placebo (P)
Biological: Pembrolizumab (K)
Drug: Paclitaxel (X)
Drug: Doxorubicin (A)
Drug: Epirubicin (E)
Drug: Cyclophosphamide (C)
Drug: Endocrine therapy
Radiation: Radiation therapy
Procedure: Surgery

First Posted Date: 2018-10-30

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1240

Registration Number: NCT03725059

Locations: 🇺🇸
Geisinger Medical Center ( Site 0052), Danville, Pennsylvania, United States
🇦🇺
Westmead Hospital ( Site 2101), Sydney, New South Wales, Australia
🇺🇸
Massachusetts General Hospital ( Site 0024), Boston, Massachusetts, United States

and more 241 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy